Latest news

Adalvo continues to strengthen its peptide & biosimilar portfolio with the addition of Pancreatin Delayed-Release Capsules, a blockbuster treatment addressing a critical need in Exocrine Pancreatic Insufficiency (EPI).  Pancreatin is the...

Adalvo, in partnership with one of the biggest Latvian medicine manufacturers Olpha, announces the first-to-market launch of Nitrofurantoin ER in the Baltic region and will expand availability to additional European markets in the...

Adalvo strengthens its specialty generics portfolio with the dossier readiness of Tofacitinib XR (11mg).  Backed by a ready-to-register EU CTD dossier, the extended-release (XR) formulation expands Adalvo’s offering and ensures broader treatment...

Adalvo, in collaboration with CNX Therapeutics, has launched Pregabalin Extended-Release (ER) tablets in the United Kingdom, strengthening its position as the first and only company to introduce this value-added formulation...

Adalvo announces the DCP approval for Macitentan 10mg film-coated tablets, marking progress in expanding access to essential treatments for pulmonary arterial hypertension (PAH).  This product is based on the reference brand...

As the world observes World Obesity Day, Adalvo highlights its commitment to addressing the global obesity crisis and its close connection to diabetes. Adalvo’s metabolism and endocrinology portfolio includes 14 INNs,...

On Rare Disease Day, Adalvo highlights its commitment to expanding access to essential treatments for patients with rare diseases. With a targeted portfolio, Adalvo continues to address unmet medical needs by providing...

Adalvo, in collaboration with Wyntra announce a significant milestone with the first launch from Adalvo’s Women's Health portfolio in the UK, reinforcing their shared commitment to expanding access to high-quality...

On World Cancer Day, Adalvo highlights its commitment to expanding access to high-quality oncology treatments. With a portfolio of 37 INNs and a total addressable market of $58 billion (according to...

Adalvo has successfully completed the fixed-dose combination development of Ambrisentan + Tadalafil film-coated tablets and is set to proceed with DCP submission this February, marking a key step towards addressing critical gaps...

Adalvo announces its DCP approval for Adapalene/Benzoyl Peroxide 0.1%/2.5% and 0.3%/2.5% Gel, positioning us as Europe's first and only company to secure approval for both strengths.  Designed for the treatment of...

Adalvo announces its DCP submission for Tacrolimus 0.03% and 0.1% Ointment, a complex, difficult-to-develop formulation designed for effective delivery, and enhancing patient accessibility. With approval anticipated for 2026, this development...

Adalvo announces the launch of the first-ever generic version of Nitrofurantoin to the UK, in collaboration with CNX Therapeutics. Having developed this product in-house, Adalvo are very proud to bring 1st generic...

Adalvo have successfully launched the first-to-market Lisdexamfetamine Oral Solution in Germany, achieved in collaboration with our strategic partner, Aristo Pharma, and co-developers, Labomed and Pharmadata. The formulation is protected by...

Adalvo has submitted the DCP for Palbociclib film-coated tablets on Day 1 following the expiry of Data Exclusivity, reinforcing our commitment to expanding our oncology portfolio. Approval is expected in 2025. Supported...

Adalvo has received DCP approval for Azelastine/Fluticasone nasal spray, strengthening its respiratory portfolio and meeting key market needs.  This approval aligns with  Adalvo’s clearly defined IP pathway, leveraging a complex, difficult-to-develop...